---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-120165"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T22:56:41.756828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagonist announces positive Phase 3 results for icotrokinra; earns $165M milestone

## Summary
- ICONIC-LEAD met co-primary endpoints: 64.7% achieved IGA 0/1, 49.6% PASI 90 at week 16 vs placebo 8.3% and 4.4%.
- ICONIC-TOTAL met primary endpoint of IGA 0/1 at week 16; results in difficult-to-treat areas.
- Earned $165M milestone under amended collaboration with Janssen; payment expected Q1 2025.
- Company remains eligible for up to $630M in future milestones and tiered royalties of 6-10% on net sales.
- Upcoming catalysts H1 2025: Phase 2b ulcerative colitis data, PsA Phase 3 start, superiority data vs deucravacitinib.

## SEC filing metadata
- accession: 0001104659-24-120165
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/0001104659-24-120165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-120165
- JSON: https://secwatch.observer/filing/0001104659-24-120165.json
- Plain text: https://secwatch.observer/filing/0001104659-24-120165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.